Discovery and Optimization of 4-Methylquinazoline Derivatives as Highly Selective PI3Kδ Inhibitors for the Treatment of Acute Lung Injury
Journal of Medicinal Chemistry · 11.06.2026 · 69 (11) · 13294-13319
DOI: 10.1021/acs.jmedchem.6c00288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.05.2026. Verfasst von Deyu Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Pek…. Hauptthemen laut MEDLINE: Acute Lung Injury, Quinazolines, Phosphoinositide-3 Kinase Inhibitors, Class I Phosphatidylinositol 3-Kinases. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Phosphoinositide 3-kinase δ (PI3Kδ) has emerged as a promising therapeutic target for inflammatory respiratory diseases. Herein, we report the design and synthesis of a novel series of 4-methylquinazoline derivatives as potent and highly selective PI3Kδ inhibitors for the treatment of acute lung injury (ALI). Guided by structure-based drug design optimization of a pan-PI3K inhibitor scaffold, the lead compound 48 was identified, exhibiting single-digit nanomolar potency against PI3Kδ and exceptional selectivity over other class I PI3K isoforms. Mechanistically, compound 48 effectively modulated immune responses by suppressing pro-inflammatory M1 macrophage polarization while promoting the anti-inflammatory M2 phenotype. Possessing favorable pharmacokinetic properties, compound 48 was evaluated in murine models of LPS-induced ALI and septic lung injury, where it significantly attenuated pulmonary edema and inflammatory infiltration. Collectively, compound 48 represents a promising preclinical candidate for the therapeutic intervention of ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
- Beijing Key Laboratory of Small Molecule Immuno-Oncology Drug Discovery and Translational Development, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, Chi…
- Department of Drug Metabolism, Beijing Key Laboratory of Key Technologies for Preclinical Research and Development of Innovative Drugs in Pharmacokinetics and Pharmacodynamics, State Key Laboratory of Digestive Health,…
ORCID-Profile: Heng Xu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Wu, D., Hao, M., Dong, S., Zhou, W., Xiong, T., Mao, C., Wang, B., Wang, M., Lin, S., Jin, J., & Xu, H. (2026). Discovery and Optimization of 4-Methylquinazoline Derivatives as Highly Selective PI3Kδ Inhibitors for the Treatment of Acute Lung Injury. Journal of Medicinal Chemistry, 69(11), 13294-13319. https://doi.org/10.1021/acs.jmedchem.6c00288
Vancouver
Wu D, Hao M, Dong S, Zhou W, Xiong T, Mao C, et al. Discovery and Optimization of 4-Methylquinazoline Derivatives as Highly Selective PI3Kδ Inhibitors for the Treatment of Acute Lung Injury. Journal of Medicinal Chemistry. 2026;69(11):13294-13319. doi:10.1021/acs.jmedchem.6c00288
BibTeX
@article{Wu2026,
author = {Wu, Deyu and Hao, Mengyao and Dong, Shuhan and Zhou, Wen and Xiong, Tianning and Mao, Chengxia and Wang, Baolian and Wang, Mingchao and Lin, Songwen and Jin, Jing and Xu, Heng},
title = {Discovery and Optimization of 4-Methylquinazoline Derivatives as Highly Selective PI3Kδ Inhibitors for the Treatment of Acute Lung Injury},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {11},
pages = {13294--13319},
doi = {10.1021/acs.jmedchem.6c00288}
}
EUVIMED